Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Angiogenesis is essential to human biology and of great clinical significance. Excessive or reduced angiogenesis can result in, or exacerbate, several disease states, including tumor formation, exudative age-related macular degeneration (AMD) and ischemia. Innovative drug delivery systems can increase the effectiveness of therapies used to treat angiogenesis-related diseases. AREAS COVERED: This paper reviews the basic biology of angiogenesis, including current knowledge about its disruption in diseases, with the focus on cancer and AMD. Anti- and proangiogenic drugs available for clinical use or in development are also discussed, as well as experimental drug delivery systems that can potentially improve these therapies to enhance or reduce angiogenesis in a more controlled manner. EXPERT OPINION: Laboratory and clinical results have shown pro- or antiangiogenic drug delivery strategies to be effective in drastically slowing disease progression. Further research in this area will increase the efficacy, specificity and duration of these therapies. Future directions with composite drug delivery systems may make possible targeting of multiple factors for synergistic effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Foreign body reaction to biomaterials
Anderson, J. M., Rodriguez, A., & Chang, D. T. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2007.11.004 · Cited by 5,138 · cited 1×
“One concern with implantable reservoirs is the potential for local inflammation or foreign body response [65,66].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 3×
“Tarrytown, NY) [28] Binds/sequesters VEGF-A and PLGF Fusion protein Wet AMD Cetuximab (Erbitux , is a registered trademark of ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company, New York, NY) [29,30] Anti-EGFR Chimeric IgG1 mAb mCRC, head and neck cancer in KRAS-wt patients”
BackgroundTumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Biodegradable polymeric nanoparticles as drug delivery devices
Soppimath, K. S., Aminabhavi, T. M., Kulkarni, A. R., & Rudzinski, W. E. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00339-4 · Cited by 3,549
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 2×
“Many angiogenic inhibitors have been developed, and several, such as bevacizumab [25], ranibizumab [26], pegaptanib [27], aflibercept [28], cetuximab [29,30], panitumumab [31], trastuzumab [32,33], gefitinib [34], erlotinib [35], sorafenib [36,37], sunitinib [38,39], temsirolimus [40] and everolimus (Table 1) [41], ha…”
BackgroundTransplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501 · cited 1×
“Polymeric gene delivery has gained attention as an alternative to viral gene delivery, which suffers from limited cargo capacity, immune response, and the possibility of insertional mutagenesis [111].”
BackgroundPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 4×
“Many angiogenic inhibitors have been developed, and several, such as bevacizumab [25], ranibizumab [26], pegaptanib [27], aflibercept [28], cetuximab [29,30], panitumumab [31], trastuzumab [32,33], gefitinib [34], erlotinib [35], sorafenib [36,37], sunitinib [38,39], temsirolimus [40] and everolimus (Table 1) [41], ha…”
BackgroundInfluential
Cited by
Drug delivery systems and materials for wound healing applications
Saghazadeh, S., Rinoldi, C., Schot, M., Kashaf, S. S., Sharifi, F., Jalilian, E., Nuutila, K., Giatsidis, G., Mostafalu, P., Derakhshandeh, H., et al. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.008 · Cited by 842
Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment
Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., Jin, G., Lu, T. J., Genin, G. M., & Xu, F. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00094 · Cited by 825
Organ-on-a-chip platforms for studying drug delivery systems
Bhise, N. S., Ribas, J., Manoharan, V., Zhang, Y. S., Polini, A., Massa, S., Dokmeci, M. R., & Khademhosseini, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.004 · Cited by 381
Self-citationPeplow, P., & Martinez, B. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.295271 · Cited by 19
“The damage to the retina causes central vision loss and eventual loss of sight if untreated (Bhise et al., 2011; Farnoodian et al., 2017).”
Background
Metadata
- Authors
- Bhise, N. S., Shmueli, R. B., Sunshine, J. C., Tzeng, S. Y., & Green, J. J.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2011-02-22
- Volume
- 8
- Issue
- 4
- Pages
- 485-504
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2111044102
- Cited by
- 65
- References
- 25
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. https://app.cochat.ai/papers/10.1517/17425247.2011.558082
- The paper
- Bhise, N. S., Shmueli, R. B., Sunshine, J. C., Tzeng, S. Y., & Green, J. J. (2011). Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425247.2011.558082
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.